46 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
7 May 24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
4:02pm
studies and clinical trials for earlier terminated programs, offset by an increase of $11.8 million of costs associated with preclinical studies
8-K
EX-99.1
hfm2gd6pz3d9q
9 Nov 23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
7:31am
S-3
lff4n
18 Aug 23
Shelf registration
8:41am
8-K
EX-99.1
dxoh6nxg 15
8 Aug 23
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.1
x3gk3p
3 Mar 22
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
4:02pm
DEFA14A
au1teb
27 Apr 21
Additional proxy soliciting materials
4:18pm